Tenalisib (RP6530)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Tenalisib (RP6530), covering 2022-10-28 to 2022-10-28. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma [Phase 1, Phase 2]